Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)

Next Previous
Trial Profile

Phase 3 Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Reltecimod as Compared to Placebo in Addition to Standard of Care in Patients With Sepsis-associated Acute Kidney Injury (SA-AKI)

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Reltecimod (Primary)
  • Indications Acute kidney injury
  • Focus Registrational; Therapeutic Use
  • Acronyms REAKT
  • Sponsors Atox Bio

Most Recent Events

  • 10 Jun 2020 Status changed from recruiting to discontinued.
  • 01 May 2019 Planned End Date changed from 1 Mar 2020 to 1 Mar 2021.
  • 01 May 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Dec 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top